Should ovarian suppression be recommended to premenopausal ER/PR positive patients?

The SOFT trial (https://www.ncbi.nlm.nih.gov/pubmed/25495490) found an improvement in DFS for combined ovarian suppression + AI compared to tamoxifen alone (the OA + Tam group was intermediate). While the overall results were positive, I think putting the results in practice requires looking at the ...